Steichen-Gersdorf E, Baumgartner M, Kreczy A, Maier H, Fink F M
Department of Pediatrics, University of Innsbruck, Austria.
Br J Cancer. 1997;76(10):1284-7. doi: 10.1038/bjc.1997.549.
Medulloblastoma is the most frequent paediatric brain tumour. Because of the uniform histology, a common genetic mechanism has been postulated. Loss of heterozygosity (LOH) studies support evidence that a candidate gene, which functions as a tumour-suppressor gene, is located in 17p13. Eighteen tumours were examined for loss of heterozygosity at 15 different loci at chromosome 17p. Nine of 18 (50%) tumours had allelic loss in 17p 13.3-13.2. The smallest region of overlap, which harbours the disease gene, includes markers from UT222 (D17S675) to UT49 (D17S731) and spans a region of less than 6 cM. Candidate genes within this region are HIC-1, a potential tumour-suppressor gene, and DPH2L, a gene that has been cloned from the ovarian critical region. The putative region excludes the p53 gene and the ABR gene, which have been favoured by others. LOH of chromosome 17p may be used as a new prognostic biological marker. Children with an allelic loss had a poorer prognosis than those patients without loss of heterozygosity (P<0.05).
髓母细胞瘤是最常见的儿童脑肿瘤。由于其组织学特征一致,人们推测存在一种共同的遗传机制。杂合性缺失(LOH)研究支持了这样的证据,即一个作为肿瘤抑制基因的候选基因位于17p13。对18个肿瘤进行了17号染色体短臂上15个不同位点的杂合性缺失检测。18个肿瘤中有9个(50%)在17p13.3 - 13.2区域存在等位基因缺失。包含致病基因的最小重叠区域包括从UT222(D17S675)到UT49(D17S731)的标记,跨度小于6厘摩。该区域内的候选基因有潜在肿瘤抑制基因HIC - 1和从卵巢关键区域克隆出的基因DPH2L。推测区域不包括其他人所青睐的p53基因和ABR基因。17号染色体短臂的杂合性缺失可作为一种新的预后生物学标志物。等位基因缺失的儿童预后比无杂合性缺失的患者差(P<0.05)。